Iovance Biotherapeutics
 | This article needs additional citations for verification. (November 2019) |
 | |
| Type | Public company |
|---|---|
| Industry | Biotechnology, Pharmaceutical, Cancer immunotherapy |
| Founded | 2007 |
| Headquarters | , U.S. |
Key people | Steven Rosenberg |
| Website | iovance |
Iovance Biotherapeutics is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.[1][2]
History[]
The company was founded in 2007 as Genesis Biopharma. In 2013, Lion merged with Genesis Biopharma And became lion bio Pharma then rebranded to Iovance in 2017.[3]
Drug pipeline[]
Iovance has a TIL treatment undergoing clinical trials against melanoma (investigational id: LN-144, tradename: Lifileucel). Iovance is investigating a TIL therapy against cervical and head and neck cancers (investigational id: LN-145).
See also[]
References[]
- ^ Garber, Ken (7 August 2019). "Pursuit of tumor-infiltrating lymphocyte immunotherapy speeds up". Nature Biotechnology. Retrieved 14 August 2019.
- ^ Adelman, Jacob (29 May 2019). "New Navy Yard lab and office complex planned for Calif. cell-therapy research firm Iovance". The Philadelphia Inquirer. Retrieved 14 August 2019.
- ^ "Genesis Biopharma Announces Completion of Merger with Lion Biotechnologies". www.businesswire.com. 2013-07-25. Retrieved 2020-01-17.
 | This United States corporation or company article is a stub. You can help Wikipedia by . |
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by . |
- United States company stubs
- Medical company stubs
- Biotechnology companies of the United States
- Pharmaceutical companies established in 2007
- Biotechnology companies established in 2013
- Companies based in California
- Health care companies based in California
- Companies listed on the Nasdaq